Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales-Reference-Cited by-同舟云学术

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

Published:2022-10 Issue:10360 Volume:400 Page:1305-1320
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Agrawal Utkarsh,Bedston Stuart,McCowan Colin,Oke Jason,Patterson Lynsey,Robertson Chris,Akbari Ashley,Azcoaga-Lorenzo Amaya,Bradley Declan T,Fagbamigbe Adeniyi Francis,Grange Zoe,Hall Elliott C R,Joy Mark,Katikireddi Srinivasa Vittal,Kerr Steven,Ritchie Lewis,Murphy Siobhán,Owen Rhiannon K,Rudan Igor,Shah Syed Ahmar,Simpson Colin R,Torabi Fatemeh,Tsang Ruby S M,de Lusignan Simon,Lyons Ronan A,O'Reilly Dermot,Sheikh Aziz

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. COVID-19: booster doses to be offered to 30 million people in UK;Wise;BMJ,2021

2. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design;Sheikh;Lancet Infect Dis,2022

3. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose;Kuhlmann;Lancet,2022

4. Protection of BNT162b2 vaccine booster against Covid-19 in Israel;Bar-On;N Engl J Med,2021

5. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study;Barda;Lancet,2021

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study;Vaccine;2024-10

2. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines;Expert Review of Vaccines;2024-09-13

3. Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital;Vaccines;2024-09-06

4. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B);International Journal of Infectious Diseases;2024-09

5. COVID-19 in the immunocompromised host;COVID-19: An Update;2024-09-01